SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS

被引：0

作者：

Genovese, M. C. ^{[1
]}

Fay, J. ^{[2
]}

Parrino, J. ^{[2
]}

Garg, A. ^{[3
]}

Van Hoogstraten, H. ^{[3
]}

Boddy, A. ^{[3
]}

Martincova, R. ^{[4
]}

Graham, N. ^{[5
]}

Simon, J. ^{[6
]}

Burmester, G. R. ^{[7
]}

机构：

[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[3] Sanofi, Bridgewater, MA USA

[4] Sanofi, Prague, Czech Republic

[5] Regeneron Pharmaceut, Tarrytown, NY USA

[6] Kohler & Milstein Res, Yucatan, Mexico

[7] Charite, Berlin, Germany

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷

关键词：

D O I：

10.1136/annrheumdis-2016-eular.3709

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0228

引用

页码：515 / 516

页数：2

共 50 条

[21] An Open-Label Dose-Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients [J].

Rutherford, Elaine ;

Stewart, Graham ;

Houston, J. Graeme ;

Jardine, Alan G. ;

Mark, Patrick B. ;

Struthers, Allan D. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (11) :1409-1414

[22] A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE- AND MULTIPLE-DOSE, DOSE FINDING STUDY AND OPEN-LABEL EXTENSION TO ASSESS THE EFFECTS OF OBETICHOLIC ACID IN PEDIATRIC PATIENTS WITH BILIARY ATRESIA [J].

Karpen, S. ;

Eliot, L. ;

Scholz, B. ;

Joshi, M. M. ;

Merrigan, M. M. ;

Sciacca, C. ;

Marmon, T. ;

Hooshmand-Rad, R. ;

MacConell, L. ;

Shapiro, D. .

JOURNAL OF HEPATOLOGY, 2016, 64 :S294-S294

[23] Evaluating dose regimens of apomorphine, an open-label study [J].

A Kongkanand ;

J Opanuraks ;

K Tantiwongse ;

N Choeypunt ;

A Tantiwong ;

T Amornvejsukit .

International Journal of Impotence Research, 2003, 15 :S10-S12

[24] Evaluating dose regimens of apomorphine, an open-label study [J].

Kongkanand, A ;

Opanuraks, J ;

Tantiwongse, K ;

Choeypunt, N ;

Tantiwong, A ;

Amornvejsukit, T .

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (Suppl 2) :S10-S12

[25] Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients [J].

Ishigooka, J ;

Murasaki, M ;

Miura, S .

PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2000, 54 (04) :467-478

[26] PHASE 2 OPEN-LABEL EXTENSION STUDY WITH DONIDALORSEN TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA [J].

Bordone, L. ;

Riedl, M. ;

Newman, K. ;

Lui, C. ;

Alexander, V. ;

Schneider, E. ;

Cohn, D. .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 :S33-S33

[27] OPEN-LABEL EXTENSION STUDY: TEZACAFTOR/IVACAFTOR, PATIENTS ≥ 12 YEARS WITH CYSTIC FIBROSIS [J].

Wainwright, C. ;

Flume, P. ;

Biner, Fischer R. ;

Downey, D. ;

Brown, C. ;

Jain, M. ;

Fischer, R. ;

De Boeck, K. ;

Campbell, D. ;

Wang, X. ;

Ahluwalia, N. ;

Owen, C. .

RESPIROLOGY, 2020, 25 :57-57

[28] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study [J].

Feagan, Brian G. ;

Panes, Julian ;

Ferrante, Marc ;

Kaser, Arthur ;

D'Haens, Geert R. ;

Sandborn, William J. ;

Louis, Edouard ;

Neurath, Markus F. ;

Franchimont, Denis ;

Dewit, Olivier ;

Seidler, Ursula ;

Kim, Kyung-Jo ;

Selinger, Christian ;

Padula, Steven J. ;

Herichova, Ivona ;

Robinson, Anne M. ;

Wallace, Kori ;

Zhao, Jun ;

Minocha, Mukul ;

Othman, Ahmed A. ;

Soaita, Adina ;

Visvanathan, Sudha ;

Hall, David B. ;

Boecher, Wulf O. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10) :671-680

[29] An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone [J].

Mattingly, G. ;

Tocco, M. ;

Cucchiaro, J. ;

Xu, J. ;

Pikalov, A. ;

Loebel, A. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 :S559-S559

[30] Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension [J].

Joan Barberà ;

Pavel Jansa ;

Elizabeth Klings ;

Arsen Ristić ;

Anne Keogh ;

Derek Solum ;

Youlan Rao ;

Rob Grover ;

Isil Saib ;

Namita Sood .

Advances in Therapy, 2024, 41 :1062-1074

← 1 2 3 4 5 →